PROPANC BIOPHARMA, INC. Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent
PROPANC BIOPHARMA, INC. (PPCB) reported Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent of $1.01 million for the 3-month period ending 2026-03-31, per its S-1 filed 2026-07-17.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent · last filed 2026-07-17
- PROPANC BIOPHARMA, INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, portion attributable to parent for the quarter ending 2026-03-31 was $1.01M.
- PROPANC BIOPHARMA, INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, portion attributable to parent for the quarter ending 2025-12-31 was $164.00K.
- PROPANC BIOPHARMA, INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, portion attributable to parent for the quarter ending 2025-09-30 was $191.00K, a 71.79% decline year-over-year.
- PROPANC BIOPHARMA, INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, portion attributable to parent for the quarter ending 2025-03-31 was -$1.34M, a 262.50% decline year-over-year.
- PROPANC BIOPHARMA, INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, portion attributable to parent for fiscal 2023 was $648.00K.
- PROPANC BIOPHARMA, INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, portion attributable to parent for fiscal 2021 was -$182.47K, a 190.93% decline from fiscal 2020.
- PROPANC BIOPHARMA, INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, portion attributable to parent for fiscal 2020 was $200.67K, a 71.70% decline from fiscal 2019.
- PROPANC BIOPHARMA, INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, portion attributable to parent for fiscal 2019 was $709.07K, a 41.91% increase from fiscal 2018.
| Period end | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-03-31 | $1.01M S-1 · filed 2026-07-17 | $1.18M derived: sum of 2 quarters · filed 2026-07-17 | $1.37M derived: sum of 3 quarters · filed 2026-07-17 | |
| 2025-12-31 | $164.00K derived: S-1 6 month − 10-Q 3 month · filed 2026-04-10 | $355.00K S-1 · filed 2026-04-10 | ||
| 2025-09-30 | $191.00K 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | $316.00K S-1 · filed 2026-07-17 | |||
| 2025-03-31 | -$1.34M S-1 · filed 2026-07-17 | -$3.59M derived: sum of 2 quarters · filed 2026-07-17 | -$2.91M derived: sum of 3 quarters · filed 2026-07-17 | -$3.24M derived: sum of 4 quarters · filed 2026-07-17 |
| 2024-12-31 | -$2.25M derived: S-1 6 month − 10-Q 3 month · filed 2026-04-10 | -$1.57M S-1 · filed 2026-04-10 | -$1.90M derived: sum of 3 quarters · filed 2026-07-17 | -$1.07M derived: sum of 4 quarters · filed 2026-07-17 |
| 2024-09-30 | $677.00K 10-Q · filed 2025-11-14 | $351.00K derived: sum of 2 quarters · filed 2026-07-17 | $1.18M derived: sum of 3 quarters · filed 2026-07-17 | $98.00K derived: sum of 4 quarters · filed 2026-07-17 |
| 2024-06-30 | -$326.00K derived: S-1 12 month − 10-Q 9 month · filed 2026-07-17 | $498.00K derived: sum of 2 quarters · filed 2026-07-17 | -$579.00K derived: sum of 3 quarters · filed 2026-07-17 | $90.00K S-1 · filed 2026-07-17 |
| 2024-03-31 | $824.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | -$253.00K derived: sum of 2 quarters · filed 2025-02-14 | $416.00K 10-Q · filed 2024-05-15 | $508.00K derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-12-31 | -$1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-14 | -$408.00K 10-Q · filed 2025-02-14 | -$316.00K derived: sum of 3 quarters · filed 2025-02-14 | |
| 2023-09-30 | $669.00K 10-Q · filed 2024-11-14 | $761.00K derived: sum of 2 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $92.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30 | $648.00K 10-K · filed 2024-09-30 | ||
| 2023-03-31 | $556.00K 10-Q · filed 2024-05-15 | |||
| 2021-09-30 | $64.19K 10-Q · filed 2021-11-12 | $95.52K derived: sum of 2 quarters · filed 2021-11-12 | $125.25K derived: sum of 3 quarters · filed 2021-11-12 | -$42.52K derived: sum of 4 quarters · filed 2021-11-12 |
| 2021-06-30 | $31.33K derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-28 | $61.05K derived: sum of 2 quarters · filed 2021-09-28 | -$106.71K derived: sum of 3 quarters · filed 2021-09-28 | -$182.47K 10-K · filed 2021-09-28 |
| 2021-03-31 | $29.72K 10-Q · filed 2021-05-14 | -$138.04K derived: sum of 2 quarters · filed 2021-05-14 | -$213.80K 10-Q · filed 2021-05-14 | -$2.23M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-12-31 | -$167.76K 10-Q · filed 2021-02-12 | -$243.52K 10-Q · filed 2021-02-12 | -$2.26M derived: sum of 3 quarters · filed 2021-11-12 | $22.96K derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-09-30 | -$75.75K 10-Q · filed 2021-11-12 | -$2.09M derived: sum of 2 quarters · filed 2021-11-12 | $190.72K derived: sum of 3 quarters · filed 2021-11-12 | -$438.77K derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | -$2.02M derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-28 | $266.48K derived: sum of 2 quarters · filed 2021-09-28 | -$363.01K derived: sum of 3 quarters · filed 2021-09-28 | $200.67K 10-K · filed 2021-09-28 |
| 2020-03-31 | $2.28M 10-Q · filed 2021-05-14 | $1.65M derived: sum of 2 quarters · filed 2021-05-14 | $2.22M 10-Q · filed 2021-05-14 | $2.41M derived: sum of 4 quarters · filed 2021-05-14 |
| 2019-12-31 | -$629.49K 10-Q · filed 2021-02-12 | -$65.81K 10-Q · filed 2021-02-12 | $124.33K derived: sum of 3 quarters · filed 2021-02-12 | $8.77K derived: sum of 4 quarters · filed 2021-02-12 |
| 2019-09-30 | $563.69K 10-Q · filed 2020-11-16 | $753.83K derived: sum of 2 quarters · filed 2020-11-16 | $638.26K derived: sum of 3 quarters · filed 2020-11-16 | $996.54K derived: sum of 4 quarters · filed 2020-11-16 |
| 2019-06-30 | $190.14K derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-01 | $74.57K derived: sum of 2 quarters · filed 2020-10-01 | $432.85K derived: sum of 3 quarters · filed 2020-10-01 | $709.07K 10-K · filed 2020-10-01 |
| 2019-03-31 | -$115.57K 10-Q · filed 2020-05-15 | $242.71K derived: sum of 2 quarters · filed 2020-05-15 | $518.93K 10-Q · filed 2020-05-15 | $990.24K derived: sum of 4 quarters · filed 2020-05-15 |
| 2018-12-31 | $358.28K 10-Q · filed 2020-02-14 | $634.50K 10-Q · filed 2020-02-14 | $1.11M derived: sum of 3 quarters · filed 2020-02-14 | $1.30M derived: sum of 4 quarters · filed 2020-02-14 |
| 2018-09-30 | $276.22K 10-Q · filed 2019-11-14 | $747.52K derived: sum of 2 quarters · filed 2019-11-14 | $946.16K derived: sum of 3 quarters · filed 2019-11-14 | $965.49K derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | $471.31K derived: 10-K 12 month − 10-Q 9 month · filed 2019-10-15 | $669.94K derived: sum of 2 quarters · filed 2019-10-15 | $689.27K derived: sum of 3 quarters · filed 2019-10-15 | $499.68K 10-K · filed 2019-10-15 |
| 2018-03-31 | $198.63K 10-Q · filed 2019-05-15 | $217.96K derived: sum of 2 quarters · filed 2019-05-15 | $28.37K 10-Q · filed 2019-05-15 | -$27.54K derived: sum of 4 quarters · filed 2019-05-15 |
| 2017-12-31 | $19.33K 10-Q · filed 2019-02-14 | -$170.26K 10-Q · filed 2019-02-14 | -$226.18K derived: sum of 3 quarters · filed 2019-02-14 | -$700.17K derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-09-30 | -$189.59K 10-Q · filed 2018-11-13 | -$245.51K derived: sum of 2 quarters · filed 2018-11-13 | -$719.50K derived: sum of 3 quarters · filed 2018-11-13 | -$237.79K derived: sum of 4 quarters · filed 2018-11-13 |
| 2017-06-30 | -$55.91K derived: 10-K 12 month − 10-Q 9 month · filed 2018-09-17 | -$529.91K derived: sum of 2 quarters · filed 2018-09-17 | -$48.19K derived: sum of 3 quarters · filed 2018-09-17 | -$273.01K 10-K · filed 2018-09-17 |
| 2017-03-31 | -$474.00K 10-Q · filed 2018-05-10 | $7.72K derived: sum of 2 quarters · filed 2018-05-10 | -$217.10K 10-Q · filed 2018-05-10 | -$60.39K derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | $481.72K 10-Q · filed 2018-02-09 | $256.90K 10-Q · filed 2018-02-09 | $413.61K derived: sum of 3 quarters · filed 2018-02-09 | $175.31K derived: sum of 4 quarters · filed 2018-02-09 |
| 2016-09-30 | -$224.82K 10-Q · filed 2017-11-09 | -$68.11K derived: sum of 2 quarters · filed 2017-11-09 | -$306.40K derived: sum of 3 quarters · filed 2017-11-09 | -$452.95K derived: sum of 4 quarters · filed 2017-11-09 |
| 2016-06-30 | $156.71K derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-28 | -$81.58K derived: sum of 2 quarters · filed 2017-09-28 | -$228.13K derived: sum of 3 quarters · filed 2017-09-28 | $30.30K 10-K · filed 2017-09-28 |
| 2016-03-31 | -$238.29K 10-Q · filed 2017-05-08 | -$384.84K derived: sum of 2 quarters · filed 2017-05-08 | -$126.41K 10-Q · filed 2017-05-08 | -$72.38K derived: sum of 4 quarters · filed 2017-05-08 |
| 2015-12-31 | -$146.55K 10-Q · filed 2017-02-14 | $111.88K 10-Q · filed 2017-02-14 | $165.91K derived: sum of 3 quarters · filed 2017-02-14 | $297.57K derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-09-30 | $258.43K 10-Q · filed 2016-11-10 | $312.46K derived: sum of 2 quarters · filed 2016-11-10 | $444.12K derived: sum of 3 quarters · filed 2016-11-10 | $547.44K derived: sum of 4 quarters · filed 2016-11-10 |
| 2015-06-30 | $54.03K derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-28 | $185.69K derived: sum of 2 quarters · filed 2016-09-28 | $289.01K derived: sum of 3 quarters · filed 2016-09-28 | $403.83K 10-K · filed 2016-09-28 |
| 2015-03-31 | $131.66K 10-Q · filed 2016-05-16 | $234.98K derived: sum of 2 quarters · filed 2016-05-16 | $349.80K 10-Q · filed 2016-05-16 | $324.26K derived: sum of 4 quarters · filed 2016-05-16 |
| 2014-12-31 | $103.32K 10-Q · filed 2016-02-16 | $218.14K 10-Q · filed 2016-02-16 | $192.60K derived: sum of 3 quarters · filed 2016-02-16 | $144.69K derived: sum of 4 quarters · filed 2016-02-16 |
| 2014-09-30 | $114.82K 10-Q · filed 2015-11-16 | $89.28K derived: sum of 2 quarters · filed 2015-11-16 | $41.38K derived: sum of 3 quarters · filed 2015-11-16 | $97.47K derived: sum of 4 quarters · filed 2015-11-16 |
| 2014-06-30 | -$25.53K derived: 10-K 12 month − 10-Q 9 month · filed 2015-09-30 | -$73.44K derived: sum of 2 quarters · filed 2015-09-30 | -$17.34K derived: sum of 3 quarters · filed 2015-09-30 | -$58.27K 10-K · filed 2015-09-30 |
| 2014-03-31 | -$47.91K 10-Q · filed 2015-05-15 | $8.19K derived: sum of 2 quarters · filed 2015-05-15 | -$32.74K 10-Q · filed 2015-05-15 | |
| 2013-12-31 | $56.10K 10-Q · filed 2015-02-17 | $15.17K 10-Q · filed 2015-02-17 | ||
| 2013-09-30 | -$40.93K 10-Q · filed 2014-11-19 | |||
| 2013-06-30 | $114.33K 10-K · filed 2014-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |